C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Trial details
- Registry ID
- NCT07037277
- Drugs studied
- Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
TrialRedline tracks 5 clinical trials sponsored by Atea Pharmaceuticals, Inc.: 3 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVNCT07037277 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir | Active not recruiting | 2026-12Estimated |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVNCT06868264 | Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) | Completed | 2026-06-18Actual |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19NCT05629962 | Bemnifosbuvir (BEM) | Completed | 2024-04-25Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVNCT05904470 | Bemnifosbuvir, Ruzasvir | Completed | 2024-12-09Actual |
| Study of AT-752 in Patients With Dengue InfectionNCT05466240 | AT-752 | Terminated | 2023-01-19Actual |
Names as written in the registry records.
NCT06868264 · Atea Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 880 participants (planned). After: 940 participants (actual).
Before: Estimated. After: Actual.
Before: Sep 2026. After: 18 Jun 2026.
Before: Active not recruiting. After: Completed.
NCT07037277 · Atea Pharmaceuticals, Inc.
Before: Recruiting. After: Active not recruiting.
NCT06868264 · Atea Pharmaceuticals, Inc.
Before: Recruiting. After: Active not recruiting.